Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.57 |
| ▸ | RAF1 | P04049 | 8/20 | 0.57 |
| ▸ | ABL1 | P00519 | 6/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440240 | 1.00 | BRAF (0.57) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL22625558 | 1.00 | BRAF (0.57) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL22625556 | 0.90 | RAF1 (0.71) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL22612954 | 0.90 | RAF1 (0.71) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL30439718 | 0.90 | RAF1 (0.71) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL30439559 | 0.88 | RAF1 (0.55) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL30440075 | 0.88 | RAF1 (0.55) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL22612742 | 0.88 | RAF1 (0.55) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL22612765 | 0.88 | RAF1 (0.55) | BRAFRAF1ABL1LCKKDR | |
| SCHEMBL22612799 | 0.86 | RAF1 (0.63) | BRAFRAF1ABL1LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885ABL1 8/4885 |
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885ABL1 8/4885 |
| US-10927111-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885ABL1 8/4885 |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885ABL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.